ProSPECTuS: Preclinical Trials

单光子发射计算机层析成像(SPECT)是医学上广泛使用的一种成像方式，它使用的是标记有伽马发射放射性同位素的放射性药物。现有的SPECT系统对身体成像的极限位置分辨率约为10 mm，对头部的极限位置分辨率约为7 mm。该系统将提供2-3 mm的图像分辨率，灵敏度为现有系统的约100倍，同时支持SPECT/MRI多模式成像。招股说明书将向英国公司开放价值超过3亿GB pa的现有市场，涵盖医疗、制药、国土安全、科学和国防。该财团在半导体辐射探测器、电子和软件设计方面拥有国际领先的声誉和多年的经验。关键的临床输入和试验通过克莱特布里奇肿瘤学中心、利物浦大学磁共振成像分析研究中心[MARIARC]和皇家利物浦大学NHS信托基金的介入放射学和医学成像小组的临床医生提供。

Single Photon Emission Computed Tomography (SPECT) is a widely used imaging modality in medicine which uses radio-pharmaceuticals labelled with gamma emitting radioisotopes. Existing SPECT systems have a limiting position resolution of about 10 mm for body imaging and 7 mm for the head. The proposed system will offer an image resolution of 2-3 mm with a sensitivity a factor of ~100 larger than existing systems, while simultaneously enabling SPECT/MRI multimodality imaging. The ProSPECTus imager will open existing markets worth in excess of £300M pa to UK companies, covering medical, pharmaceutical, homeland security, science and defence. The consortium brings an internationally leading reputation and many years experience with semiconductor radiation detectors, electronics and software design. Key clinical input and trials are provided through Clinicians at the Clatterbridge Centre for Oncology , the University of Liverpool Magnetic Resonance Imaging Analysis Research Centre [MARIARC] and the Interventional Radiology and Medical Imaging Group at the Royal Liverpool University NHS Trust.